GSK plc (LON:GSK) Given Average Rating of "Moderate Buy" by Brokerages

GSK plc (LON:GSK - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the six analysts that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is GBX 1,862.50 ($25.27).

A number of brokerages recently commented on GSK. JPMorgan Chase & Co. reiterated an "underweight" rating on shares of GSK in a research note on Friday, March 28th. Shore Capital reiterated a "buy" rating on shares of GSK in a research note on Wednesday, April 30th.

Insiders Place Their Bets

In other GSK news, insider Emma Walmsley sold 5,473 shares of the stock in a transaction that occurred on Tuesday, May 6th. The shares were sold at an average price of GBX 1,449 ($19.66), for a total transaction of £79,303.77 ($107,618.09). Also, insider Wendy Becker bought 536 shares of the firm's stock in a transaction on Thursday, March 20th. The shares were acquired at an average price of GBX 1,515 ($20.56) per share, for a total transaction of £8,120.40 ($11,019.68). Company insiders own 1.61% of the company's stock.

GSK Stock Performance

Shares of GSK stock traded down GBX 25.37 ($0.34) on Friday, reaching GBX 1,486.13 ($20.17). The stock had a trading volume of 9,006,570 shares, compared to its average volume of 14,608,582. The company has a quick ratio of 0.73, a current ratio of 0.81 and a debt-to-equity ratio of 114.64. The firm's 50-day moving average is GBX 1,414.30 and its two-hundred day moving average is GBX 1,411.01. The firm has a market capitalization of £60.30 billion, a price-to-earnings ratio of 24.01, a P/E/G ratio of 1.24 and a beta of 0.31. GSK has a 12 month low of GBX 1,242.50 ($16.86) and a 12 month high of GBX 1,678.68 ($22.78).

GSK (LON:GSK - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The company reported GBX 44.90 ($0.61) EPS for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. On average, research analysts expect that GSK will post 175.980975 EPS for the current fiscal year.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.